Direct targeting of DUX4 will likely be the primary therapeutic strategy for FSHD, because once begun, any technique that inhibits DUX4 expression or function should block multiple pathogenic changes that are dependent on DUX4 transcriptional activity (Mitsuhashi et al., 2018). Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.